Genelux Corporation
- GNLX
- NASDAQ
- Biotechnology
- Oncolytic Viral Immunotherapy
$2.41
Today −0.41%Quote Oct 19, 2026, 02:05 PM UTC
−4.35%over the last month
Max drawdown −11.1%From 1-month high −7.3%3 months −17.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$109.0M
Quote Oct 19
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$17.33
+619.1% from here
Floor
$2.40
0.2% below price
Where the price sits
3 analysts
Analyst range, low to high
$16.00$20.00
- Price $2.41
- Resistance $2.43
- Consensus $17.33
The price is just above its floor and right under resistance. Analysts' average target sits about 619% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GNLXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
26
Founded
2001